NEW YORK, Oct. 21, 2020 /PRNewswire/ -- Rowley Law
PLLC is investigating potential securities law violations by
Cleveland BioLabs, Inc. (NASDAQ: CBLI) and its board of directors
concerning the proposed acquisition of the company by Cytocom, Inc.
Cleveland BioLabs stockholders are expected to own 39% of the
combined company. The Transaction is expected to close in the first
quarter of 2021.
If you are a stockholder of Cleveland BioLabs, Inc. and are
interested in obtaining additional information regarding this
investigation, please visit us at:
http://www.rowleylawpllc.com/investigation/cbli/. You may also
contact Shane Rowley, Esq. at Rowley
Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at
email@example.com, or by telephone at 914-400-1920 or
Rowley Law PLLC represents shareholders nationwide in class
actions and derivative lawsuits in complex corporate litigation.
For more information about the firm and its attorneys, please visit
Attorney Advertising. Prior results do not guarantee a similar
SOURCE Rowley Law PLLC